Stem cells, particularly mesenchymal stem cells (MSCs) and adipose-derived stem cells (ADSCs), play a significant role in enhancing skin wound healing by promoting tissue regeneration, modulating inflammation, and stimulating angiogenesis.
Stem cell therapy for skin wounds leverages the cells’ ability to differentiate into various skin cell types (e.g., keratinocytes, fibroblasts, endothelial cells) and their secretion of cytokines and growth factors that foster a regenerative microenvironment.
Recent clinical trial evidence indicates that stem cell therapies—especially those using mesenchymal stem cells (MSCs) and adipose-derived stromal cells accelerate wound healing, reducing ulcer size, and improving tissue quality compared to standard wound care, with a favorable safety profile and promising long-term outcomes.
MSCs and ADSCs are especially attractive due to their ease of isolation, low immunogenicity, and robust paracrine effects, which include promoting angiogenesis, reducing inflammation, and encouraging extracellular matrix remodeling.
These mechanisms accelerate wound closure, improve cosmesis, and may reduce scarring.
Stem cells can be delivered via topical application, injection, or incorporation into scaffolds and hydrogels.
Recent trends include using stem cell-derived exosomes or secretome as cell-free therapies, which mimic the beneficial effects of stem cells while potentially reducing safety concerns associated with live cell transplantation.
Clinical studies have shown efficacy in treating chronic wounds such as diabetic ulcers, venous ulcers, post-surgical defects, with evidence of reduced pain, faster healing, and improved tissue quality.
Stem cell therapies result in faster wound closure, reduced ulcer area, and lower major amputation rates in chronic wounds such as diabetic foot ulcers, venous ulcers, and pressure sores, compared to conventional treatments alone.
A RCT reported a 72% reduction in wound size at 12 weeks with MSC therapy versus standard care.
Adipose-derived MSCs (AD-MSCs) and stromal vascular fraction (SVF) cells are safe and effective, with no major adverse events reported in clinical studies.
In summary, stem cells and their derivatives represent a promising adjunctive therapy for chronic and complex skin wounds, primarily through their regenerative, immunomodulatory, and pro-angiogenic properties.